Betamethasone 17,21-dipropionateCAS# 5593-20-4 |
- Dexamethasone dipropionate
Catalog No.:BCC8934
CAS No.:55541-30-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 5593-20-4 | SDF | Download SDF |
| PubChem ID | 21800 | Appearance | Powder |
| Formula | C28H37FO7 | M.Wt | 504.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Betamethasone 17,21-dipropionate | ||
| Solubility | DMSO : ≥ 150 mg/mL (297.27 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate | ||
| SMILES | CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC | ||
| Standard InChIKey | CIWBQSYVNNPZIQ-XYWKZLDCSA-N | ||
| Standard InChI | InChI=1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Betamethasone 17,21-dipropionate Dilution Calculator
Betamethasone 17,21-dipropionate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9818 mL | 9.9088 mL | 19.8177 mL | 39.6354 mL | 49.5442 mL |
| 5 mM | 0.3964 mL | 1.9818 mL | 3.9635 mL | 7.9271 mL | 9.9088 mL |
| 10 mM | 0.1982 mL | 0.9909 mL | 1.9818 mL | 3.9635 mL | 4.9544 mL |
| 50 mM | 0.0396 mL | 0.1982 mL | 0.3964 mL | 0.7927 mL | 0.9909 mL |
| 100 mM | 0.0198 mL | 0.0991 mL | 0.1982 mL | 0.3964 mL | 0.4954 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Betamethasone dipropionate is a glucocorticoid steroid with anti-inflammatory and immunosuppressive abilities.
In Vivo:Betamethasone dipropionate is a super high potency corticosteroid used to treat inflammatory skin conditions such as dermatitis, eczema and psoriasis. It is a synthetic analog of the adrenal corticosteroids.
- Pennogenin 3-O-beta-chacotrioside
Catalog No.:BCN6707
CAS No.:55916-52-4
- Polyphyllin VI
Catalog No.:BCN1053
CAS No.:55916-51-3
- Cucurbitacin R
Catalog No.:BCN7877
CAS No.:55903-92-9
- Friedelin
Catalog No.:BCN5747
CAS No.:559-74-0
- beta-Amyrin
Catalog No.:BCN5746
CAS No.:559-70-6
- Morolic acid
Catalog No.:BCN7475
CAS No.:559-68-2
- 6-Hydroxysugiol
Catalog No.:BCN3154
CAS No.:55898-07-2
- Boc-D-Lys(Z)-OH
Catalog No.:BCC3423
CAS No.:55878-47-2
- 6-beta-Hydroxyhyoscyamine
Catalog No.:BCN1915
CAS No.:55869-99-3
- VER-49009
Catalog No.:BCC5297
CAS No.:558640-51-0
- 1-Methoxymethyl-beta-carboline
Catalog No.:BCN7911
CAS No.:55854-60-9
- AMD-070
Catalog No.:BCC1357
CAS No.:558447-26-0
- Methylpheophorbide A
Catalog No.:BCN7998
CAS No.:5594-30-9
- Pseudohypericin
Catalog No.:BCN6348
CAS No.:55954-61-5
- ARC 239 dihydrochloride
Catalog No.:BCC6851
CAS No.:55974-42-0
- Nitazoxanide
Catalog No.:BCC3824
CAS No.:55981-09-4
- Methylthiouracil
Catalog No.:BCC4800
CAS No.:56-04-2
- 2,4-Diamino-6-hydroxypyrimidine
Catalog No.:BCC6658
CAS No.:56-06-4
- 4-Aminobutanoic acid
Catalog No.:BCN2187
CAS No.:56-12-2
- Cystamine dihydrochloride
Catalog No.:BCC6344
CAS No.:56-17-7
- Cantharidin
Catalog No.:BCN1280
CAS No.:56-25-7
- Tetraethylammonium chloride
Catalog No.:BCC7554
CAS No.:56-34-8
- H-Gly-OH
Catalog No.:BCC2946
CAS No.:56-40-6
- H-Ala-OH
Catalog No.:BCC3190
CAS No.:56-41-7
Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study.[Pubmed:28960334]
Contact Dermatitis. 2018 Jan;78(1):76-82.
BACKGROUND: Corticosteroids are among the most commonly used topical drugs. Contact allergy to these exists, but can be easily missed. Corticosteroid screening markers have been included in the baseline series with the aim of detecting most of the sensitized patients. OBJECTIVES: To assess the prevalence of contact allergy to topical corticosteroids in Spain and examine the usefulness of corticosteroid markers to detect contact allergy to corticosteroids. METHODS: In total, 3699 patients referred to 20 dermatology departments across Spain for patch testing with the baseline series, including budesonide and tixocortol pivalate, were also tested with six supplementary corticosteroids (methylprednisolone aceponate, mometasone furoate, prednicarbate, clobetasol propionate, betamethasone 17-valerate, and Betamethasone 17,21-dipropionate). Additionally, 2547 (68.8%) patients were tested with hydrocortisone 17-butyrate. RESULTS: Fifty-four patients showed positive reactions to at least one of all tested corticosteroids (1.46%). Thirty-nine (1.05%) reacted to at least one of the additionally tested corticosteroids; among these, 24 of 39 (61.5%) did not react to any of the corticosteroid allergy screening markers tested. CONCLUSIONS: More than half of the patients who were allergic to the additionally tested corticosteroids were not detected with the corticosteroid allergy markers. An update of the corticosteroid allergy screening markers is encouraged, with consideration of group 3 corticosteroids.
